Document Detail

Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials.
MedLine Citation:
PMID:  19900019     Owner:  NLM     Status:  MEDLINE    
Hypertension is a comorbidity of Type 2 diabetes, and blood pressure lowering has been shown to reduce cardiovascular (CV) and renal disease progression in this population. Angiotensin-converting enzyme (ACE)-inhibitors have demonstrated reduction in CV mortality and myocardial infarction, stroke, and heart failure in patients with diabetes. Evidence suggests that angiotensin receptor blockers (ARBs) have similar CV protective effects, particularly in patients post-myocardial infarction and in those with heart failure, and their renoprotective effects have reduced proteinuria in patients with or without diabetes. In addition, ARBs have been shown to reduce diabetic nephropathy and complications related to nephropathy. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint trial (ONTARGET) is the first trial to demonstrate that the ARB, telmisartan, is as effective as the ACE-inhibitor, ramipril, in CV protection in a high-risk, ACE-tolerant population. Whether all ARBs are equally cardioprotective is uncertain. Data indicate that the beneficial effects of telmisartan may be drug specific rather than constitute a 'class effect.'
Samy I McFarlane
Related Documents :
1702049 - Dietary fish oil enhances renal hypertrophy in experimental diabetes.
15326549 - Alpha-spinasterol isolated from the root of phytolacca americana and its pharmacologica...
15724789 - Therapeutic controversies in hypertension management: angiotensin converting enzyme (ac...
16388709 - Relationship between reduced bcl-2 expression in circulating mononuclear cells and earl...
3993659 - The changing natural history of nephropathy in type i diabetes.
2699009 - The relationship between glomerular structure and function in insulin-dependent diabetes.
24490009 - Frequency of odontogenic periradicular lesions in diabetic patients.
25145409 - Factors associated with remission and/or regression of microalbuminuria in type 2 diabe...
7168549 - Hepatic acetylator phenotype in diabetes mellitus.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  7     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-11-10     Completed Date:  2010-02-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1363-71     Citation Subset:  IM    
Division of Endocrinology, Medical Director of Clinical Research, College of Medicine, State University of New York-Downstate Medical Center, Kings County Hospital Center, 450 Clarkson Avenue, Box 50, Brooklyn, NY 11203, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Clinical Trials as Topic
Diabetes Mellitus, Type 2 / complications,  drug therapy*
Hypertension / complications,  drug therapy*
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus.
Next Document:  Recent changes in the landscape of combination RAS blockade.